☆ 4.2 Meeting Abstract

Onasemnogene aveparvovec gene therapy for spinal muscular atrophy type 1 (SMA1): Phase 3 study update (STR1VE-EU)

NEUROMUSCULAR DISORDERS (2020)

Journal

NEUROMUSCULAR DISORDERS

Volume 30, Issue -, Pages S121-S121

Publisher

PERGAMON-ELSEVIER SCIENCE LTD

DOI: 10.1016/j.nmd.2020.08.257

Keywords

-

Categories

Clinical Neurology Neurosciences

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.2

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

No Data Available

No Data Available

No Data Available

© Peeref 2019-2024. All rights reserved.